XORTX Therapeutics Inc (TSE:XRTX)
:XRTX
XRTX Stock Chart & Stats
C$0.78
C$0.05(2.94%)
At close: 4:00 PM EST
C$0.78
C$0.05(2.94%)
Day’s Range― - ―
52-Week RangeC$0.49 - C$1.97
Previous CloseN/A
Volume514.00
Average Volume (3M)11.08K
Market Cap
C$835.47K
Enterprise Value-C$534.85K
Total Cash (Recent Filing)C$1.19M
Total Debt (Recent Filing)C$51.11K
Price to Earnings (P/E)―
Beta0.59
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding1,392,444
10 Day Avg. Volume30,736
30 Day Avg. Volume11,079
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.35
Revenue Forecast (FY)C$3.25M
Bulls Say, Bears Say
Bulls Say
Focused Therapeutic Pipeline On Oxypurinol For Kidney DiseaseA concentrated pipeline around oxypurinol for ADPKD and chronic kidney disease gives a clear, durable strategic focus. Specialization in a single mechanism and indication set builds institutional knowledge, streamlines R&D prioritization, and supports targeted regulatory and clinical development planning over months.
Low Leverage And Minimal DebtVery low debt materially reduces near-term solvency and interest burden, preserving financial flexibility. For a development-stage biotech this structural conservatism lowers bankruptcy risk and leaves more optionality for financing or strategic partnerships without immediate pressure from creditors.
Improving Cash Outflows And Moderated Cash BurnA multi-year trend of reduced operating and free cash outflows signals better cost control and more efficient use of capital. This structural improvement extends runway duration and makes near-term financing needs smaller, aiding program continuity and preserving value while clinical milestones are pursued.
Bears Say
No Revenue And Persistent Operating LossesAbsence of any revenue base is a fundamental constraint: the company cannot self-fund operations and has no product-derived cash generation. Over multiple quarters this structural deficiency necessitates external capital, limits reinvestment capacity, and elevates execution risk until commercialization is achieved.
Continued Reliance On External Financing Due To Cash BurnSustained negative operating and free cash flows create an ongoing need for equity or other financing. This structural dependency increases dilution risk, can constrain R&D cadence if markets tighten, and makes strategic planning sensitive to capital market access over the coming months.
Material Erosion Of Equity Base And Negative ROESharp shrinkage of shareholders' equity reduces the company's financial buffer against setbacks and limits balance-sheet capacity for absorbing future losses. Deeply negative ROE signals persistent value erosion, complicating future capital raises and weakening bargaining power with potential partners or acquirers.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was C$0.48 and its highest was C$1.97 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is C$835.47K.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is May 14, 2026 which is in 38 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on Mar 26, 2026. The company reported -C$0.07 earnings per share for the quarter, beating the consensus estimate of -C$0.233 by C$0.163.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,392,444 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -C$0.07 in its last earnings report, beating expectations of -C$0.233. Following the earnings report the stock price went down -20.313%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---